| PLIANT THERAPEUTICS |
| USA |
| Gesundheit |
| US7291391057 / A2P4YV |
| 9PT (Frankfurt) / PLRX (NASDAQ) |
| FRA:9PT, ETR:9PT, 9PT:GR, NASDAQ:PLRX |
| - |
| https://pliantrx.com/ |
|
Pliant Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics for fibrotic diseases, solid tumors, and muscular dystrophies. The company leverages integrin receptor biology to..
>Volltext.. |
| 70.8 Mio. EUR |
| -66.93 Mio. EUR |
| - |
| -131.75 Mio. EUR |
| -129.38 Mio. EUR |
| -2.11 EUR |
| 25.21 Mio. EUR |
| 39.37 Mio. EUR |
| -111.18 Mio. EUR |
| 11.67 |
| - |
| 37.41% |
| - |
| - |
| - |
| - |
| PLIANT THERAPEUTICS, PLIANT THERAPEUTIC |
| 04.04.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|